Drug Profile
Research programme: stroke therapeutics - NeuroProtect
Alternative Names: NPI-503; NPI-505Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NeuroProtect Inc
- Class
- Mechanism of Action ASIC channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebral ischaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cerebral-ischaemia(Prevention) in USA
- 26 Nov 2007 Preclinical trials in Cerebral ischaemia in USA (unspecified route)